Allan WP - Search Results

1

Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.

Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC. Ritke MK, et al. Among authors: allan wp. Mol Pharmacol. 1994 Jul;46(1):58-66. Mol Pharmacol. 1994. PMID: 8058057

2

Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.

Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC. Ritke MK, et al. Among authors: allan wp. Mol Pharmacol. 1995 Nov;48(5):798-805. Mol Pharmacol. 1995. PMID: 7476909

3

Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.

Ritke MK, Rusnak JM, Lazo JS, Allan WP, Dive C, Heer S, Yalowich JC. Ritke MK, et al. Among authors: allan wp. Mol Pharmacol. 1994 Oct;46(4):605-11. Mol Pharmacol. 1994. PMID: 7969039

4

Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells.

Ritke MK, Bergoltz VV, Allan WP, Yalowich JC. Ritke MK, et al. Among authors: allan wp. Biochem Pharmacol. 1994 Aug 3;48(3):525-33. doi: 10.1016/0006-2952(94)90282-8. Biochem Pharmacol. 1994. PMID: 8068039

5

Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC. Ritke MK, et al. Among authors: allan wp. Br J Cancer. 1994 Apr;69(4):687-97. doi: 10.1038/bjc.1994.131. Br J Cancer. 1994. PMID: 8142256 Free PMC article.

6

Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.

Fattman CL, Allan WP, Hasinoff BB, Yalowich JC. Fattman CL, et al. Among authors: allan wp. Biochem Pharmacol. 1996 Aug 23;52(4):635-42. doi: 10.1016/0006-2952(96)00338-3. Biochem Pharmacol. 1996. PMID: 8759037

7

Chemical synthesis and biological activity of a novel fluorescent etoposide derivative.

Lazo JS, Li T, Woo ES, Settineri CE, Allan WP, Yalowich JC. Lazo JS, et al. Among authors: allan wp. Biochem Pharmacol. 1997 Mar 7;53(5):715-22. doi: 10.1016/s0006-2952(96)00906-9. Biochem Pharmacol. 1997. PMID: 9113091

8

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.

Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC. Hasinoff BB, et al. Among authors: allan wp. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453. Mol Pharmacol. 2001. PMID: 11179439

9

Mechanisms of nitric oxide protection against tert-butyl hydroperoxide-induced cytotoxicity in iNOS-transduced human erythroleukemia cells.

Yalowich JC, Gorbunov NV, Kozlov AV, Allan W, Kagan VE. Yalowich JC, et al. Biochemistry. 1999 Aug 17;38(33):10691-8. doi: 10.1021/bi9829229. Biochemistry. 1999. PMID: 10451363

10

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.

Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC. Hasinoff BB, et al. Among authors: allan wp. Biochem Pharmacol. 1997 Jun 15;53(12):1843-53. doi: 10.1016/s0006-2952(97)00013-0. Biochem Pharmacol. 1997. PMID: 9256159

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters